Pliant Therapeutics Inc
NASDAQ:PLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
US |
|
PYC Therapeutics Ltd
ASX:PYC
|
AU |
|
R
|
Reed's Inc
AMEX:REED
|
US |
|
Esports Mogul Ltd
ASX:ESH
|
AU |
|
R
|
Richter Gedeon Vegyeszeti Gyar Nyrt
BET:RICHTER
|
HU |
|
S
|
Shanghai Dragon Corp
SSE:600630
|
CN |
|
S
|
Shenzhen Sinovatio Technology Co Ltd
SZSE:002912
|
CN |
|
Beijer Alma AB
STO:BEIA B
|
SE |
|
T
|
Techindia Nirman Ltd
NSE:TECHIN
|
IN |
|
Orell Fuessli AG
SIX:OFN
|
CH |
|
T
|
TPI Polene PCL
SET:TPIPL
|
TH |
Pliant Therapeutics Inc
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 91 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. The company focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 91 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. The company focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
